knowledge -WSS

knowledge

author：knowledge 2025-10-01 10:56:55 - browse：35

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Merck CEO won’t testify in Senate, citing no expertise in drug prices

focus

WSS

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Former reverend arrested for allegedly killing 8

Why patients can’t get everything they want on drug pricing

What it's like to live with paralysis for one psychologist

Merck, Johnson & Johnson CEOs will testify on high drug prices

A new crop of companies is reshaping the health data economy

leisure time

knowledge

focus

ChatGPT in medicine: STAT answers readers' burning questions

Former reverend arrested for allegedly killing 8

United colonoscopy coverage change 'may cost lives,' doctors say

Pancreatic cancer early detection could be helped by AI

Cancer drug shortages should be causing more outrage

FTC sues over Novant Health acquisition of two N.C. hospitals

The high cost of giving birth even with insurance

In the gardens at Boston Children's Hospital, families find sanctuary

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Bernie Sanders is gearing up to subpoena pharma CEOs

focus

New clues to why women have higher risk of autoimmune disorders

CDC Director Mandy Cohen on transparency, trust, and health

What it's like to live with paralysis for one psychologist

In the gardens at Boston Children's Hospital, families find sanctuary

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

CDC Director Mandy Cohen on transparency, trust, and health

focus

focus

knowledge

hotspot